Quanterix Announces Investor Presentation at Canaccord Growth Conference

Quanterix to Present at the Canaccord Genuity 45th Annual Growth Conference

Rhea-AI Impact

(Low)

Rhea-AI Sentiment

(Neutral)

Tags

conferences

08/11/2025 - 07:00 AM

BILLERICA, Mass.--(BUSINESS WIRE)-- (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced that its executive leadership team will present at the Canaccord Genuity 45^th Annual Growth Conference in Boston, Massachusetts on Tuesday, August 12^th, at 3:30 p.m. ET. Quanterix will also host one-on-one meetings with institutional investors during the conference.

Webcast Information

The live webcast presentation can be accessed from the section of the company鈥檚 website at . A replay of the webcast will be available for a limited period following the conference.

About Quanterix

Quanterix is a global leader in ultra-sensitive biomarker detection, enabling breakthroughs in disease research, diagnostics, and drug development. Its proprietary Simoa^庐 technology delivers industry-leading sensitivity, allowing researchers to detect and quantify biomarkers in blood and other fluids at concentrations far below traditional limits. With more than 3,600 peer-reviewed publications, Quanterix has been a trusted partner to the scientific community for nearly two decades. In 2025, Quanterix acquired Akoya Biosciences, The Spatial Biology Company^庐, adding multiplexed tissue imaging with single-cell resolution to its portfolio and 1,396 installed instruments. Together, the combined company offers a uniquely integrated platform that connects biology across blood and tissue鈥攁dvancing precision medicine from discovery to diagnostics. Learn more at .